Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study
| العنوان: | Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study |
|---|---|
| المؤلفون: | Babak Afrough, Mar Cabeza-Cabrerizo, Ulrike Arnold, Jonathan H.J. Baum, Lamine Koivogui, Christopher H. Logue, Luam Ghebreghiorghis, Nicole Hetzelt, Katja Nitzsche, Rahel Lemma Yenamaberhan, Cèline Gurry, Daouda Sissoko, Lauren A. Cowley, Ralf Krumkamp, Martin Rudolf, Carlos M. Castro, Kilian Stoecker, Roman Wölfel, Beate Becker-Ziaja, Sophie Duraffour, Inês Vitoriano, Isabel García-Dorival, Erna Fleischmann, Natasha Y. Rickett, Antonino Di Caro, Marc Mertens, Joseph Akoi Bore, Sarah Meisel, Theresa Enkirch, Sékou Ditinn Cissé, Liana E. Kafetzopoulou, Anna Jaeger, Martin Gabriel, Abigail Kosgei, Fara Raymond Koundouno, Lisa L. Carter, Boubacar Diallo, N’Faly Magassouba, Jürgen May, Tobias Holm, Johanna Repits, Katrin Singethan, Julia Hinzmann, Denis Malvy, Elisa Pallasch, Xavier Anglaret, Stephanie Wurr, Patrick Drury, Antonio Mazzarelli, Eva Lorenz, Sakoba Keita, Claire Levy Marchal, Osvaldo Miranda, Alseny-Modet Camara, Romy Kerber, Géraldine Colin, Sylvain Juchet, Jacques Seraphin Kolié, Stephan Günther, Miles W. Carroll, Abdoul Habib Beavogui, Sabrina Bockholt, Pierre Formenty, Janine Michel, Alvaro Camino, Eeva Kuisma, Giuseppe Ippolito, Livia Victoria Patrono, Andreas Sachse, Jan-Peter Böttcher, Amadou Bah, Elsa Gayle Zekeng, Jasmine Portmann |
| المساهمون: | Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| المصدر: | JOURNAL OF INFECTIOUS DISEASES Journal of Infectious Diseases Journal of Infectious Diseases, Oxford University Press (OUP), 2019, 220 (2), pp.195-202. ⟨10.1093/infdis/jiz078⟩ The Journal of Infectious Diseases |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Compassionate Use Trials, Male, 0301 basic medicine, viruses, Kaplan-Meier Estimate, Disease, medicine.disease_cause, epidemic, 0302 clinical medicine, CHEMISTRY, Immunology and Allergy, 030212 general & internal medicine, Child, Univariate analysis, Middle Aged, Viral Load, Ebolavirus, ddc, 3. Good health, Infectious Diseases, Child, Preschool, Pyrazines, Viruses, Female, mobile laboratory, Life Sciences & Biomedicine, Adult, medicine.medical_specialty, Adolescent, Immunology, Ebola virus disease, Favipiravir, DIAGNOSIS, Antiviral Agents, Microbiology, Major Articles and Brief Reports, Young Adult, 03 medical and health sciences, SIERRA-LEONE, Internal medicine, medicine, Humans, In patient, ddc:610, Retrospective Studies, Cycle threshold, Science & Technology, Ebola virus, business.industry, Retrospective cohort study, Hemorrhagic Fever, Ebola, Amides, Filovirus, VIRAL LOAD, 030104 developmental biology, Blood chemistry, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Guinea, 610 Medizin und Gesundheit, business |
| الوصف: | In 2015, favipiravir was administered on a compassionate-use basis to patients with Ebola virus disease in Guinea. This study reveals a trend toward improved survival in favipiravir-treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time. Background In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. The cycle threshold (Ct) of an Ebola virus–specific reverse transcription–polymerase chain reaction assay and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to patients with EVD on a compassionate-use basis. Methods To reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome. Results The case-fatality rate in favipiravir-treated patients was lower than in untreated patients (42.5% [31 of 73] vs 57.8% [52 of 90]; P = .053 by univariate analysis). In multivariate regression analysis, a higher Ct and a younger age were associated with survival (P < .001), while favipiravir treatment showed no statistically significant effect (P = .11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (P = .015). The study also showed characteristic changes in blood chemistry findings in patients who died, compared with survivors. Conclusions Consistent with the JIKI trial, this retrospective study revealed a trend toward improved survival in favipiravir- treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time. |
| وصف الملف: | application/pdf; Print |
| اللغة: | English |
| تدمد: | 0022-1899 1537-6613 |
| DOI: | 10.1093/infdis/jiz078⟩ |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e82b8acb3a37901ef1f93dc953e3b506 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e82b8acb3a37901ef1f93dc953e3b506 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00221899 15376613 |
|---|---|
| DOI: | 10.1093/infdis/jiz078⟩ |